Ondine Biomedical, Inc. (OBI) Price & Analysis

Compare

12 Followers

OBI Stock Chart & Stats

Day’s Range― - ―

52-Week Range6.00p - 18.50p

Previous CloseN/A

Volume7.12K

Average Volume (3M)483.32K

Market Cap

£71.28M

Enterprise Value21.10M

Total Cash (Recent Filing)£1.22M

Total Debt (Recent Filing)£351.00K

Price to Earnings (P/E)―

Beta0.16

Next Earnings

May 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding518,366,940

10 Day Avg. Volume296,629

30 Day Avg. Volume483,320

Financial Highlights & Ratios

PEG Ratio0.53

Price to Book (P/B)6.29

Price to Sales (P/S)21.10

P/FCF Ratio-2.79

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£13.50

Price Target Upside-1.82% Downside

Rating ConsensusHold

Number of Analyst Covering1

Ondine Biomedical, Inc. News

Ondine Biomedical’s Steriwave Piloted at Royal Papworth Hospital

An update from Ondine Biomedical, Inc. ( ($GB:OBI) ) is now available. Ondine Biomedical Inc. has announced a...

8d ago

Ondine Biomedical Expands Steriwave Adoption and Advances Clinical Trials in H1 2025

Ondine Biomedical, Inc. ( ($GB:OBI) ) just unveiled an announcement. Ondine Biomedical Inc. reported significant commercial expansion and...

14d ago

Ondine Biomedical’s Steriwave Adopted by Mater Hospital to Tackle AMR in Cancer Care

Ondine Biomedical, Inc. ( ($GB:OBI) ) has provided an update. Ondine Biomedical Inc. announced that The Mater Hospital...

17d ago

Ondine Biomedical to Announce Interim Financial Results

Ondine Biomedical, Inc. ( ($GB:OBI) ) has shared an announcement. Ondine Biomedical Inc. announced it will release its...

21d ago

Ondine Biomedical’s Steriwave Shows Major Economic and Health Benefits at ICPIC 2025

Ondine Biomedical, Inc. ( ($GB:OBI) ) has shared an update. Ondine Biomedical Inc. presented significant findings at the...

21d ago

Ondine Biomedical’s Steriwave Technology Proves Effective Against Drug-Resistant Fungus

The latest announcement is out from Ondine Biomedical, Inc. ( ($GB:OBI) ). Ondine Biomedical Inc. has announced that...

25d ago

Ondine Biomedical Grants 300,000 Share Options to Consultant

Ondine Biomedical, Inc. ( ($GB:OBI) ) has provided an update. Ondine Biomedical Inc. has announced the grant of...

28d ago

Ondine Biomedical’s Steriwave Gains Global Attention on CNBC

Ondine Biomedical, Inc. ( ($GB:OBI) ) has shared an announcement. Ondine Biomedical’s Steriwave nasal photodisinfection technology was recently...

30d ago

Ondine Biomedical to Present Steriwave Health Economic Data at ICPIC 2025

Ondine Biomedical, Inc. ( ($GB:OBI) ) has shared an announcement. Ondine Biomedical Inc. has been invited to present...

1M ago

Ondine Biomedical Updates Total Voting Rights

Ondine Biomedical, Inc. ( ($GB:OBI) ) has issued an update. Ondine Biomedical Inc. announced a correction to its...

1M ago

OBI FAQ

What was Ondine Biomedical, Inc.’s price range in the past 12 months?

Ondine Biomedical, Inc. lowest share price was 6.00p and its highest was 18.50p in the past 12 months.

What is Ondine Biomedical, Inc.’s market cap?

Ondine Biomedical, Inc.’s market cap is £71.28M.

When is Ondine Biomedical, Inc.’s upcoming earnings report date?

Ondine Biomedical, Inc.’s upcoming earnings report date is May 14, 2026 which is in 216 days.

How were Ondine Biomedical, Inc.’s earnings last quarter?

Currently, no data Available

Is Ondine Biomedical, Inc. overvalued?

According to Wall Street analysts Ondine Biomedical, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ondine Biomedical, Inc. pay dividends?

Ondine Biomedical, Inc. does not currently pay dividends.

What is Ondine Biomedical, Inc.’s EPS estimate?

Ondine Biomedical, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ondine Biomedical, Inc. have?

Ondine Biomedical, Inc. has 518,366,940 shares outstanding.

What happened to Ondine Biomedical, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Ondine Biomedical, Inc.?

Currently, no hedge funds are holding shares in GB:OBI

Ondine Biomedical, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-430.02%

Trailing 12-Months

Asset Growth

108.68%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ondine Biomedical, Inc.

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

Ondine Biomedical, Inc. (OBI) Earnings & Revenues

Historic Earnings Reports

OBI Stock 12 Month Forecast

Average Price Target

13.50p

▼(-1.82% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"5p","15":"15p","25":"25p","35":"35p","45":"45p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">13.50p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">13.50p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">13.50p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,15,25,35,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2022","6":"Jan<br/>2023","9":"Oct<br/>2024","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.5,14.423076923076923,14.346153846153847,14.26923076923077,14.192307692307692,14.115384615384615,14.038461538461538,13.961538461538462,13.884615384615385,13.807692307692308,13.73076923076923,13.653846153846153,13.576923076923077,{"y":13.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.5,14.423076923076923,14.346153846153847,14.26923076923077,14.192307692307692,14.115384615384615,14.038461538461538,13.961538461538462,13.884615384615385,13.807692307692308,13.73076923076923,13.653846153846153,13.576923076923077,{"y":13.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.5,14.423076923076923,14.346153846153847,14.26923076923077,14.192307692307692,14.115384615384615,14.038461538461538,13.961538461538462,13.884615384615385,13.807692307692308,13.73076923076923,13.653846153846153,13.576923076923077,{"y":13.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.5,"date":1651363200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":43,"date":1654041600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":43.5,"date":1656633600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":37.75,"date":1659312000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.5,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.5,"date":1661990400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.5,"date":1672531200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.25,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >